Bristol Myers Squibb vs Johnson & Johnson
Prices at close . Model readings .
Bristol Myers Squibb
$60.57−1.59%- Market value
- $124.05B
- P/E
- 13.0
- 1 year
- +44.3%
Johnson & Johnson
$271.04+0.86%- Market value
- $663.67B
- P/E
- 30.4
- 1 year
- +44.9%
Price change, with the S&P 500 as a benchmark
Percent change in each close since the start of the chosen range, for both companies and the S&P 500 (SPY). Daily closes over the last year, weekly before that and monthly before five years.
How the two compare
On the latest closes (28 Oct 2026), Johnson & Johnson is the larger company by market value ($663.67B against $124.05B). Over the past year Bristol Myers Squibb returned +44.3% and Johnson & Johnson +44.9%, while the S&P 500 returned +12.7%. The latest filed P/E is 13.0 for Bristol Myers Squibb and 30.4 for Johnson & Johnson, and the operating margin 22.6% against -7.1%. Over the next 21 sessions the model expects +0.09% for Bristol Myers Squibb, with a 57% chance of a rise, and −0.17% for Johnson & Johnson, with a 24% chance. Bristol Myers Squibb's long-run fair value is $67.39, a gap of +11.3% to its price; the long-run model view is positive. Johnson & Johnson's long-run fair value is $224.06, a gap of −17.3% to its price; the long-run model view is negative.
What the model expects
Expected returns and the chance of a rise from our forecasting models, and the long-run fair value against the price. Readings, not advice.
How the prices moved
Price change over each period, with the S&P 500 (SPY) for comparison.
What the market pays
Size and the multiples from the latest filed quarter. A P/E on losses reads n/m.
How much of revenue becomes profit
Margins and returns on capital from the latest filing; revenue, net income and earnings per share over the trailing twelve months.
How fast the business grew
Change against the same quarter a year earlier.
Balance sheet and quality scores
Leverage, liquidity and two published scores: Altman Z (below 1.8 the distress zone, above 3 the safe zone) and Piotroski F (0 to 9).
How the shares trade
Volatility, sensitivity to the market, the deepest fall, short interest and how closely the two move together.
Bristol Myers Squibb or Johnson & Johnson: common questions
Which is larger by market value, Bristol Myers Squibb or Johnson & Johnson?
Johnson & Johnson, at $663.67B against $124.05B for Bristol Myers Squibb, on the latest closes (28 Oct 2026).
Which has the higher P/E ratio, Bristol Myers Squibb or Johnson & Johnson?
Johnson & Johnson has the higher latest filed P/E, 30.4; Bristol Myers Squibb's is 13.0. Filings: quarter to 30 Jun 2026 and 27 Sep 2026.
How did Bristol Myers Squibb and Johnson & Johnson move over the past year against the S&P 500?
Over the past year Bristol Myers Squibb returned +44.3% and Johnson & Johnson +44.9%, while the S&P 500 returned +12.7%. Prices at close 28 Oct 2026.
What does the model expect for Bristol Myers Squibb and Johnson & Johnson over the next month?
+0.09% for Bristol Myers Squibb with a 57% chance of a rise, and −0.17% for Johnson & Johnson with a 24% chance, over the next 21 sessions. Model readings 28 Oct 2026. These are model readings, not advice.
How do the operating margins of Bristol Myers Squibb and Johnson & Johnson compare?
The operating margin is 22.6% for Bristol Myers Squibb and -7.1% for Johnson & Johnson, and the gross margin 71.3% against 68.1%. Filings: quarter to 30 Jun 2026 and 27 Sep 2026.
Do Bristol Myers Squibb and Johnson & Johnson shares move together?
Over the past year the correlation of their daily returns was 0.45 (loosely together); 1 means they always move together, 0 unrelated, −1 opposite. Prices at close 28 Oct 2026.
Model readings are research estimates, not investment advice. Prices: daily closes. Fundamentals: the latest SEC filings. Short interest: FINRA, settlement 30 Sep 2026. A dash means the figure is not in our data; it is never shown as zero. The model view follows a published rule: next month by the sign of the expected return, the long run positive at a fair value 10% or more above the price and negative at 10% or more below it.